Cargando…

Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database

Detalles Bibliográficos
Autor principal:	Picaut, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267525/ https://www.ncbi.nlm.nih.gov/pubmed/30390198 http://dx.doi.org/10.1007/s40261-018-0723-4

Ejemplares similares

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Cisplatin-Associated Aortic Thrombosis: A Review of Cases Reported to the FDA Adverse Event Reporting System
por: Nadeau Nguyen, Michelle C., et al.
Publicado: (2021)

Comment on Fomepizole and Acetaminophen Overdose
por: Nguyen, Kim-Long R., et al.
Publicado: (2023)

Reply: Cisplatin-Associated Aortic Thrombosis: A Review of Cases Reported to the FDA Adverse Event Reporting System
por: Cameron, Alan C., et al.
Publicado: (2021)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Botulinum toxin in hemifacial spasm: Revisited
por: Singh, Sukhbir
Publicado: (2013)

Efficacy of botulinum toxin type A in new daily persistent headache
por: Spears, Roderick C.
Publicado: (2008)

Medication overdose data analysis: a review of medication error reports in the FDA adverse event reporting system (FAERS)
por: Ni, Jiaqi, et al.
Publicado: (2023)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Response to “Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA PRO Guidance”
por: Ascher, Benjamin, et al.
Publicado: (2020)

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
por: Spiegel, Lauren L., et al.
Publicado: (2020)

Botulinum toxin type-A therapy in cluster headache: a novel molecular mechanism
por: Namazi, Hamid
Publicado: (2008)

Lower lid entropion correction with botulinum toxin injection
por: Deka, Amarendra, et al.
Publicado: (2010)

Botulinum Toxin Follow-up Clinics: Training Implications
por: Larner, A
Publicado: (2000)

Botulinum Toxin A for Gummy Smile—Keep It Simple
por: Dimasi, Ioanna, et al.
Publicado: (2023)

Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
por: Putzke, Joerg, et al.
Publicado: (2021)

A Simple Botulinum Toxin Injection Technique for Masseter Reduction
por: Ng, Zhi Yang, et al.
Publicado: (2021)

Botulinum Toxin A in the Management of Acne Vulgaris: Evidence and Recommendations
por: Birkett, Liam, et al.
Publicado: (2022)

Comment on “Piriformis syndrome: pain response outcomes following CT-guided injection and incremental value of botulinum toxin injection” by Yan et al.
por: Güleç, Gamze Gül, et al.
Publicado: (2022)

Use of botulinum toxin type A in Frey's syndrome
por: Gualberto, Gustavo Vieira, et al.
Publicado: (2017)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Comments on: Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study
por: Singh, Manisha, et al.
Publicado: (2020)

Botulinum toxin in the management of acquired motor fusion deficiency: The missing links
por: Pandey, Pramod Kumar, et al.
Publicado: (2010)

Vitreous hemorrhage following inadvertent intra-ocular injection of botulinum toxin
por: Agrawal, Siddharth, et al.
Publicado: (2015)

Subcutaneous Injection of Botulinum Toxin-A in Postherpetic Neuralgia During Pregnancy
por: Jain, Pratik, et al.
Publicado: (2017)

Botulinum A Toxin and Laser Therapy: Evidence and Recommendations for Combination Treatment
por: Chan, Kayen, et al.
Publicado: (2023)

Response to comments on: Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study
por: Pellegrini, Marco, et al.
Publicado: (2020)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
por: Kavanagh, Kevin T, et al.
Publicado: (2019)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
por: Kan, Yusuke, et al.
Publicado: (2021)

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2021)

Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age
por: ABE, Junko, et al.
Publicado: (2015)

Ultrasound guided injection of botulinum toxin into the salivary glands of children with neurological disorders
por: Matsuoka, Marcia Wang, et al.
Publicado: (2016)

Reversible Dry Beri-Beri Postintragastric Botulinum Toxin Injection for Weight Reduction
por: Kesav, Praveen, et al.
Publicado: (2023)

Comment on "Efficacy and adverse events of cold vs hot polypectomy: A meta-analysis"
por: Sun, Huan-Huan, et al.
Publicado: (2017)

Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”
por: Silverman, Bernard, et al.
Publicado: (2018)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
por: Trumbo, Henry, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_99jca1ej7gqdqo020k744qg0og